Personalized Medicine and Epigenomics Market
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Reagents
1.2.3 Kits
1.2.4 Instruments
1.2.5 Enzymes
1.2.6 Services
1.3 Market by Application
1.3.1 Global Personalized Medicine and Epigenomics Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Oncology
1.3.3 Non-Oncology
1.3.4 Cancer Drug Technology
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Personalized Medicine and Epigenomics Market Perspective (2018-2032)
2.2 Personalized Medicine and Epigenomics Growth Trends by Region
2.2.1 Personalized Medicine and Epigenomics Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Personalized Medicine and Epigenomics Historic Market Size by Region (2018-2023)
2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Region (2023-2032)
2.3 Personalized Medicine and Epigenomics Market Dynamics
2.3.1 Personalized Medicine and Epigenomics Industry Trends
2.3.2 Personalized Medicine and Epigenomics Market Drivers
2.3.3 Personalized Medicine and Epigenomics Market Challenges
2.3.4 Personalized Medicine and Epigenomics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalized Medicine and Epigenomics Players by Revenue
3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2018-2023)
3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2018-2023)
3.2 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
3.4 Global Personalized Medicine and Epigenomics Market Concentration Ratio
3.4.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2022
3.5 Personalized Medicine and Epigenomics Key Players Head office and Area Served
3.6 Key Players Personalized Medicine and Epigenomics Product Solution and Service
3.7 Date of Enter into Personalized Medicine and Epigenomics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Personalized Medicine and Epigenomics Breakdown Data by Type
4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2018-2023)
4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2023-2032)
5 Personalized Medicine and Epigenomics Breakdown Data by Application
5.1 Global Personalized Medicine and Epigenomics Historic Market Size by Application (2018-2023)
5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Personalized Medicine and Epigenomics Market Size (2018-2032)
6.2 North America Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
6.3 North America Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Personalized Medicine and Epigenomics Market Size (2018-2032)
7.2 Europe Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
7.3 Europe Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size (2018-2032)
8.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
8.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Personalized Medicine and Epigenomics Market Size (2018-2032)
9.2 Latin America Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
9.3 Latin America Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size (2018-2032)
10.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2018-2023)
10.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
11.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Affymetrix
11.2.1 Affymetrix Company Detail
11.2.2 Affymetrix Business Overview
11.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
11.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.2.5 Affymetrix Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Detail
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
11.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.3.5 Agilent Technologies Recent Development
11.4 Astellas Pharmaceuticals
11.4.1 Astellas Pharmaceuticals Company Detail
11.4.2 Astellas Pharmaceuticals Business Overview
11.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
11.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.4.5 Astellas Pharmaceuticals Recent Development
11.5 BAYER AG
11.5.1 BAYER AG Company Detail
11.5.2 BAYER AG Business Overview
11.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
11.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.5.5 BAYER AG Recent Development
11.6 Bio Vision
11.6.1 Bio Vision Company Detail
11.6.2 Bio Vision Business Overview
11.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
11.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.6.5 Bio Vision Recent Development
11.7 Celgene Corp.
11.7.1 Celgene Corp. Company Detail
11.7.2 Celgene Corp. Business Overview
11.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
11.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.7.5 Celgene Corp. Recent Development
11.8 Emd Millipore
11.8.1 Emd Millipore Company Detail
11.8.2 Emd Millipore Business Overview
11.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
11.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.8.5 Emd Millipore Recent Development
11.9 Epigenomics AG
11.9.1 Epigenomics AG Company Detail
11.9.2 Epigenomics AG Business Overview
11.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
11.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.9.5 Epigenomics AG Recent Development
11.10 Epigentex
11.10.1 Epigentex Company Detail
11.10.2 Epigentex Business Overview
11.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
11.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.10.5 Epigentex Recent Development
11.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
11.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Detail
11.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
11.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
11.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Detail
11.12.2 Gilead Sciences Business Overview
11.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
11.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.12.5 Gilead Sciences Recent Development
11.13 Glaxosmithkline
11.13.1 Glaxosmithkline Company Detail
11.13.2 Glaxosmithkline Business Overview
11.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
11.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.13.5 Glaxosmithkline Recent Development
11.14 Illumina Inc.
11.14.1 Illumina Inc. Company Detail
11.14.2 Illumina Inc. Business Overview
11.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
11.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.14.5 Illumina Inc. Recent Development
11.15 Johnson & Johnson
11.15.1 Johnson & Johnson Company Detail
11.15.2 Johnson & Johnson Business Overview
11.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
11.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.15.5 Johnson & Johnson Recent Development
11.16 Karus Therapeutics Limited
11.16.1 Karus Therapeutics Limited Company Detail
11.16.2 Karus Therapeutics Limited Business Overview
11.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
11.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.16.5 Karus Therapeutics Limited Recent Development
11.17 Laboratory Corp. Of America Holdings
11.17.1 Laboratory Corp. Of America Holdings Company Detail
11.17.2 Laboratory Corp. Of America Holdings Business Overview
11.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
11.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.17.5 Laboratory Corp. Of America Holdings Recent Development
11.18 LES Laboratoires Servier
11.18.1 LES Laboratoires Servier Company Detail
11.18.2 LES Laboratoires Servier Business Overview
11.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
11.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.18.5 LES Laboratoires Servier Recent Development
11.19 Merck
11.19.1 Merck Company Detail
11.19.2 Merck Business Overview
11.19.3 Merck Personalized Medicine and Epigenomics Introduction
11.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.19.5 Merck Recent Development
11.20 Naturewise Biotech & Medicals Corp.
11.20.1 Naturewise Biotech & Medicals Corp. Company Detail
11.20.2 Naturewise Biotech & Medicals Corp. Business Overview
11.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
11.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.20.5 Naturewise Biotech & Medicals Corp. Recent Development
11.21 Novartis Pharma AG
11.21.1 Novartis Pharma AG Company Detail
11.21.2 Novartis Pharma AG Business Overview
11.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
11.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.21.5 Novartis Pharma AG Recent Development
11.22 Oncolys Biopharma Inc.
11.22.1 Oncolys Biopharma Inc. Company Detail
11.22.2 Oncolys Biopharma Inc. Business Overview
11.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
11.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.22.5 Oncolys Biopharma Inc. Recent Development
11.23 Orchid Chemicals & Pharmaceuticals Limited
11.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Detail
11.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
11.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
11.24 Progen Pharmaceuticals Limited
11.24.1 Progen Pharmaceuticals Limited Company Detail
11.24.2 Progen Pharmaceuticals Limited Business Overview
11.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.24.5 Progen Pharmaceuticals Limited Recent Development
11.25 Quest Diagnostics
11.25.1 Quest Diagnostics Company Detail
11.25.2 Quest Diagnostics Business Overview
11.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
11.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.25.5 Quest Diagnostics Recent Development
11.26 Roche Holding AG
11.26.1 Roche Holding AG Company Detail
11.26.2 Roche Holding AG Business Overview
11.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
11.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.26.5 Roche Holding AG Recent Development
11.27 Rubicon Genomics
11.27.1 Rubicon Genomics Company Detail
11.27.2 Rubicon Genomics Business Overview
11.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
11.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.27.5 Rubicon Genomics Recent Development
11.28 Takeda Pharmaceutical Company Limited
11.28.1 Takeda Pharmaceutical Company Limited Company Detail
11.28.2 Takeda Pharmaceutical Company Limited Business Overview
11.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
11.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023)
11.28.5 Takeda Pharmaceutical Company Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2032
Table 2. Key Players of Reagents
Table 3. Key Players of Kits
Table 4. Key Players of Instruments
Table 5. Key Players of Enzymes
Table 6. Key Players of Services
Table 7. Global Personalized Medicine and Epigenomics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2032
Table 8. Global Personalized Medicine and Epigenomics Market Size by Region (US$ Million): 2018 VS 2022 VS 2032
Table 9. Global Personalized Medicine and Epigenomics Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Personalized Medicine and Epigenomics Market Share by Region (2018-2023)
Table 11. Global Personalized Medicine and Epigenomics Forecasted Market Size by Region (2023-2032) & (US$ Million)
Table 12. Global Personalized Medicine and Epigenomics Market Share by Region (2023-2032)
Table 13. Personalized Medicine and Epigenomics Market Trends
Table 14. Personalized Medicine and Epigenomics Market Drivers
Table 15. Personalized Medicine and Epigenomics Market Challenges
Table 16. Personalized Medicine and Epigenomics Market Restraints
Table 17. Global Personalized Medicine and Epigenomics Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Personalized Medicine and Epigenomics Market Share by Players (2018-2023)
Table 19. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalized Medicine and Epigenomics as of 2022)
Table 20. Ranking of Global Top Personalized Medicine and Epigenomics Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Personalized Medicine and Epigenomics Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Personalized Medicine and Epigenomics Product Solution and Service
Table 24. Date of Enter into Personalized Medicine and Epigenomics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Personalized Medicine and Epigenomics Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2018-2023)
Table 28. Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2023-2032) & (US$ Million)
Table 29. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2023-2032)
Table 30. Global Personalized Medicine and Epigenomics Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2018-2023)
Table 32. Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2023-2032) & (US$ Million)
Table 33. Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2023-2032)
Table 34. North America Personalized Medicine and Epigenomics Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Personalized Medicine and Epigenomics Market Size by Country (2023-2032) & (US$ Million)
Table 36. Europe Personalized Medicine and Epigenomics Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Personalized Medicine and Epigenomics Market Size by Country (2023-2032) & (US$ Million)
Table 38. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2023-2032) & (US$ Million)
Table 40. Latin America Personalized Medicine and Epigenomics Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Personalized Medicine and Epigenomics Market Size by Country (2023-2032) & (US$ Million)
Table 42. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2018-2023) & (US$ Million)
Table 43. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2023-2032) & (US$ Million)
Table 44. Abbott Laboratories Company Detail
Table 45. Abbott Laboratories Business Overview
Table 46. Abbott Laboratories Personalized Medicine and Epigenomics Product
Table 47. Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 48. Abbott Laboratories Recent Development
Table 49. Affymetrix Company Detail
Table 50. Affymetrix Business Overview
Table 51. Affymetrix Personalized Medicine and Epigenomics Product
Table 52. Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 53. Affymetrix Recent Development
Table 54. Agilent Technologies Company Detail
Table 55. Agilent Technologies Business Overview
Table 56. Agilent Technologies Personalized Medicine and Epigenomics Product
Table 57. Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 58. Agilent Technologies Recent Development
Table 59. Astellas Pharmaceuticals Company Detail
Table 60. Astellas Pharmaceuticals Business Overview
Table 61. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product
Table 62. Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 63. Astellas Pharmaceuticals Recent Development
Table 64. BAYER AG Company Detail
Table 65. BAYER AG Business Overview
Table 66. BAYER AG Personalized Medicine and Epigenomics Product
Table 67. BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 68. BAYER AG Recent Development
Table 69. Bio Vision Company Detail
Table 70. Bio Vision Business Overview
Table 71. Bio Vision Personalized Medicine and Epigenomics Product
Table 72. Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 73. Bio Vision Recent Development
Table 74. Celgene Corp. Company Detail
Table 75. Celgene Corp. Business Overview
Table 76. Celgene Corp. Personalized Medicine and Epigenomics Product
Table 77. Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 78. Celgene Corp. Recent Development
Table 79. Emd Millipore Company Detail
Table 80. Emd Millipore Business Overview
Table 81. Emd Millipore Personalized Medicine and Epigenomics Product
Table 82. Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 83. Emd Millipore Recent Development
Table 84. Epigenomics AG Company Detail
Table 85. Epigenomics AG Business Overview
Table 86. Epigenomics AG Personalized Medicine and Epigenomics Product
Table 87. Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 88. Epigenomics AG Recent Development
Table 89. Epigentex Company Detail
Table 90. Epigentex Business Overview
Table 91. Epigentex Personalized Medicine and Epigenomics Product
Table 92. Epigentex Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 93. Epigentex Recent Development
Table 94. Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Detail
Table 95. Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
Table 96. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and EpigenomicsProduct
Table 97. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 98. Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
Table 99. Gilead Sciences Company Detail
Table 100. Gilead Sciences Business Overview
Table 101. Gilead Sciences Personalized Medicine and EpigenomicsProduct
Table 102. Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 103. Gilead Sciences Recent Development
Table 104. Glaxosmithkline Company Detail
Table 105. Glaxosmithkline Business Overview
Table 106. Glaxosmithkline Personalized Medicine and EpigenomicsProduct
Table 107. Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 108. Glaxosmithkline Recent Development
Table 109. Illumina Inc. Company Detail
Table 110. Illumina Inc. Business Overview
Table 111. Illumina Inc. Personalized Medicine and EpigenomicsProduct
Table 112. Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 113. Illumina Inc. Recent Development
Table 114. Johnson & Johnson Company Detail
Table 115. Johnson & Johnson Business Overview
Table 116. Johnson & Johnson Personalized Medicine and EpigenomicsProduct
Table 117. Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 118. Johnson & Johnson Recent Development
Table 119. Karus Therapeutics Limited Company Detail
Table 120. Karus Therapeutics Limited Business Overview
Table 121. Karus Therapeutics Limited Personalized Medicine and EpigenomicsProduct
Table 122. Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 123. Karus Therapeutics Limited Recent Development
Table 124. Laboratory Corp. Of America Holdings Company Detail
Table 125. Laboratory Corp. Of America Holdings Business Overview
Table 126. Laboratory Corp. Of America Holdings Personalized Medicine and EpigenomicsProduct
Table 127. Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 128. Laboratory Corp. Of America Holdings Recent Development
Table 129. LES Laboratoires Servier Company Detail
Table 130. LES Laboratoires Servier Business Overview
Table 131. LES Laboratoires Servier Personalized Medicine and EpigenomicsProduct
Table 132. LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 133. LES Laboratoires Servier Recent Development
Table 134. Merck Company Detail
Table 135. Merck Business Overview
Table 136. Merck Personalized Medicine and EpigenomicsProduct
Table 137. Merck Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 138. Merck Recent Development
Table 139. Naturewise Biotech & Medicals Corp. Company Detail
Table 140. Naturewise Biotech & Medicals Corp. Business Overview
Table 141. Naturewise Biotech & Medicals Corp. Personalized Medicine and EpigenomicsProduct
Table 142. Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 143. Naturewise Biotech & Medicals Corp. Recent Development
Table 144. Novartis Pharma AG Company Detail
Table 145. Novartis Pharma AG Business Overview
Table 146. Novartis Pharma AG Personalized Medicine and EpigenomicsProduct
Table 147. Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 148. Novartis Pharma AG Recent Development
Table 149. Oncolys Biopharma Inc. Company Detail
Table 150. Oncolys Biopharma Inc. Business Overview
Table 151. Oncolys Biopharma Inc. Personalized Medicine and EpigenomicsProduct
Table 152. Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 153. Oncolys Biopharma Inc. Recent Development
Table 154. Orchid Chemicals & Pharmaceuticals Limited Company Detail
Table 155. Orchid Chemicals & Pharmaceuticals Limited Business Overview
Table 156. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and EpigenomicsProduct
Table 157. Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 158. Orchid Chemicals & Pharmaceuticals Limited Recent Development
Table 159. Progen Pharmaceuticals Limited Company Detail
Table 160. Progen Pharmaceuticals Limited Business Overview
Table 161. Progen Pharmaceuticals Limited Personalized Medicine and EpigenomicsProduct
Table 162. Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 163. Progen Pharmaceuticals Limited Recent Development
Table 164. Quest Diagnostics Company Detail
Table 165. Quest Diagnostics Business Overview
Table 166. Quest Diagnostics Personalized Medicine and EpigenomicsProduct
Table 167. Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 168. Quest Diagnostics Recent Development
Table 169. Roche Holding AG Company Detail
Table 170. Roche Holding AG Business Overview
Table 171. Roche Holding AG Personalized Medicine and EpigenomicsProduct
Table 172. Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 173. Roche Holding AG Recent Development
Table 174. Rubicon Genomics Company Detail
Table 175. Rubicon Genomics Business Overview
Table 176. Rubicon Genomics Personalized Medicine and EpigenomicsProduct
Table 177. Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 178. Rubicon Genomics Recent Development
Table 179. Takeda Pharmaceutical Company Limited Company Detail
Table 180. Takeda Pharmaceutical Company Limited Business Overview
Table 181. Takeda Pharmaceutical Company Limited Personalized Medicine and EpigenomicsProduct
Table 182. Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2018-2023) & (US$ Million)
Table 183. Takeda Pharmaceutical Company Limited Recent Development
Table 184. Research Programs/Design for This Report
Table 185. Key Data Information from Secondary Sources
Table 186. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Personalized Medicine and Epigenomics Market Share by Type: 2022 VS 2032
Figure 2. Reagents Features
Figure 3. Kits Features
Figure 4. Instruments Features
Figure 5. Enzymes Features
Figure 6. Services Features
Figure 7. Global Personalized Medicine and Epigenomics Market Share by Application in 2022 & 2032
Figure 8. Oncology Case Studies
Figure 9. Non-Oncology Case Studies
Figure 10. Cancer Drug Technology Case Studies
Figure 11. Personalized Medicine and Epigenomics Report Years Considered
Figure 12. Global Personalized Medicine and Epigenomics Market Size (US$ Million), Year-over-Year: 2018-2032
Figure 13. Global Personalized Medicine and Epigenomics Market Size, (US$ Million), 2018 VS 2022 VS 2032
Figure 14. Global Personalized Medicine and Epigenomics Market Share by Region: 2022 VS 2032
Figure 15. Global Personalized Medicine and Epigenomics Market Share by Players in 2022
Figure 16. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalized Medicine and Epigenomics as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Personalized Medicine and Epigenomics Revenue in 2022
Figure 18. North America Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 19. North America Personalized Medicine and Epigenomics Market Share by Country (2018-2032)
Figure 20. United States Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 21. Canada Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 22. Europe Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 23. Europe Personalized Medicine and Epigenomics Market Share by Country (2018-2032)
Figure 24. Germany Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 25. France Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 26. U.K. Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 27. Italy Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 28. Russia Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 29. Nordic Countries Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 30. Asia-Pacific Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 31. Asia-Pacific Personalized Medicine and Epigenomics Market Share by Region (2018-2032)
Figure 32. China Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 33. Japan Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 34. South Korea Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 35. Southeast Asia Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 36. India Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 37. Australia Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 38. Latin America Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 39. Latin America Personalized Medicine and Epigenomics Market Share by Country (2018-2032)
Figure 40. Mexico Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 41. Brazil Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 42. Middle East & Africa Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 43. Middle East & Africa Personalized Medicine and Epigenomics Market Share by Country (2018-2032)
Figure 44. Turkey Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 45. Saudi Arabia Personalized Medicine and Epigenomics Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 46. Abbott Laboratories Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 47. Affymetrix Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 48. Agilent Technologies Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 49. Astellas Pharmaceuticals Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 50. BAYER AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 51. Bio Vision Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 52. Celgene Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 53. Emd Millipore Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 54. Epigenomics AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 55. Epigentex Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 56. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 57. Gilead Sciences Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 58. Glaxosmithkline Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 59. Illumina Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 60. Johnson & Johnson Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 61. Karus Therapeutics Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 62. Laboratory Corp. Of America Holdings Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 63. LES Laboratoires Servier Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 64. Merck Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 65. Naturewise Biotech & Medicals Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 66. Novartis Pharma AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 67. Oncolys Biopharma Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 68. Orchid Chemicals & Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 69. Progen Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 70. Quest Diagnostics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 71. Roche Holding AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 72. Rubicon Genomics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 73. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2018-2023)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
Industry Market Size
